NASDAQ
81.55USD
+5.04 (+6.59%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.8B
P/E
—
EPS
—
Beta
1.88
52W range
60.105-156
Day range
77.89–83.39
Open
78.66
Prev close
76.51
Volume
1.5M
Avg volume
1.3M
Dividend
0.00
IPO
2019-05-02
https://www.businesswire.com/news/home/20260803377333/en/TransMedics-Group-Inc.-Investor-News-Rosen-Law-Firm-Announces-Investigation-of-Breaches-of-Fiduciary-Duties-by-the-Directors-and-Officers-of-TransMedics-Group-Inc.-%E2%80%93-TMDX/ · 8/4/2026-0.60
https://www.zacks.com/stock/news/2949650/transmedics-completes-pad-aviation-investment-to-expand-in-europe?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2949650 · 7/7/2026+0.80
https://seekingalpha.com/article/4919192-transmedics-the-margins-must-recover · 7/1/2026+0.60
https://seekingalpha.com/article/4913253-transmedics-why-im-still-bullish-after-the-collapse · 6/9/2026+0.60
https://www.zacks.com/stock/news/2916190/tmdx-dips-after-posting-q1-earnings-revenue-miss-margins-fall?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2916190 · 5/6/2026
https://www.defenseworld.net/2026/03/15/transmedics-group-inc-tmdx-position-increased-by-arrowmark-colorado-holdings-llc.html · 3/15/2026+0.50
https://www.fool.com/investing/2026/02/28/got-5000-transmedics-could-be-a-hightech-organtran/ · 2/28/2026+0.80
https://www.zacks.com/stock/news/2873386/ahead-of-transmedics-tmdx-q4-earnings-get-ready-with-wall-street-estimates-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2873386 · 2/23/2026+0.80
https://www.prnewswire.com/news-releases/transmedics-to-present-at-upcoming-march-investor-conferences-302689917.html · 2/17/2026+0.10
https://www.fool.com/investing/2026/01/11/stocks-to-love-in-2026/ · 1/12/2026+1.00
https://www.defenseworld.net/2025/12/27/transmedics-group-inc-tmdx-shares-purchased-by-osaic-holdings-inc.html · 12/27/2025+0.40
https://www.fool.com/investing/2025/12/01/3-top-stocks-to-buy-in-december/ · 12/2/2025+0.90
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
